[Dongcheng Pharmaceutical: The marketing application for bemiparin sodium injection was accepted by the State Food and Drug Administration] On September 9, Dongcheng Pharmaceutical (002675.SZ) announced that the company's wholly-owned subsidiary Dongcheng Northern received the "Notice of Acceptance" for the marketing license application for bemiparin sodium injection approved and issued by the State Food and Drug Administration. This drug is a low molecular weight heparin, suitable for preventing coagulation in extracorporeal circulation during hemodialysis and preventing thromboembolic diseases in patients with general surgery and orthopedic surgery. Currently, only the original version of this product is on the market in China, and no generic drugs are on the market. In 2025, domestic all-terminal hospital sales will be 300 million yuan.